The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib

Yekeduz E., Aktas E. G., KÖKSOY E. B., Dogan N., ÜRÜN Y., UTKAN G.

FUTURE ONCOLOGY, cilt.18, ss.1067-1076, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2021-1182
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1067-1076
  • Anahtar Kelimeler: colon cancer, drug interaction, rectal cancer, regorafenib, COMPREHENSIVE GERIATRIC ASSESSMENT, POTENTIAL-DRUG INTERACTIONS, PALLIATIVE CARE, ELDERLY-PATIENTS, RISK-FACTORS, CHEMOTHERAPY, SURVIVAL, MEDICATIONS
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim: To evaluate polypharmacy (PP) in patients with metastatic colorectal cancer receiving regorafenib. Methods: Patients with metastatic colorectal cancer receiving regorafenib were included and divided into two categories by their PP status: PP- (<5 regular drug use/day) and PP+ (>= 5 regular drug use/day). Results: 80 patients were included. 31 (38.7%) patients had PP. The median number of drugs used was three and seven in PP- and PP+ patients, respectively. Antiemetics (26.5%) and antacids (48.4%) were the most common drugs used by PP- and PP+ patients, respectively. In multivariate analysis, the risk of death was higher in PP+ patients (hazard ratio: 2.1; 95% CI: 1.2-3.7; p = 0.005). Conclusion: PP was an independent prognostic factor for overall survival in patients with metastatic colorectal cancer receiving regorafenib.